|
|
|
|
||
W/link to the IVPR library: Re: Pfizer authorizes an $11B share buyback At some point, SGMO will want a great deal of money to move as many IVPR targets forward as quickly as possible. If the first application demonstrates efficacy and safety, NEVER in the history of biotechnology will there have been a platform even within a full order of magnitude*1 as low a cost of drug development, nor within a full order of magnitude as little time to go from selection of target to IND approval, nor with an order of magnitude as small a risk of failure. And there will only have been a handful of previous drugs with such a high probability (close to certainty after the first succes) of as high an efficacy and in as high a proportion of patients as the appropriate*2 MDG targets for the IVPR will all be. (all discussed in great detail very many times here already and organized in the "IVPR library" (link at the top of the SGMO message board page) *1 i.e.: with a cost even less than 10 times what SGMO's IVPR will be *2 to be suitable for the IVPR platform, an MGD must be all of : where both the protein is expressed at constant levels, where it is expressed in the liver or general circulation AND where it is the lack of the correctly formed protein that causes the problem and the presence of the missformed protein does not cause problems on its own. (for diseases where the missformed protein causes problems (Huntington's etc) the |
return to message board, top of board |